Koch, DK
Claus Koch, Kobenhavn K DK
Patent application number | Description | Published |
---|---|---|
20100196927 | METHOD OF DETERMINING FUNCTIONAL DEFICIENCIES IN THE COMPLEMENT SYSTEM - The present invention relates to a method of in vitro determining functional deficiencies in the lectin pathway of the complement system, the method comprises the steps of (a) diluting a mammalian sample of body fluid with a diluent comprising one or more inhibitors of the activation of the classical and the alternative pathways of the complement system; (b) activating the lectin pathway of the complement system in the sample obtained from (a); and (c) determining in the sample obtained from (b) the activation of one or more of the complement factors C3, C4, or one or more of the components of the C5-C9 complex. The invention furthermore relates to kits for use in connection with the above-mentioned method, the first kit comprises i) a first component comprising a carrier, one or more inhibitors of the classical and the alternative complement pathways and a diluent; and ii) a second component comprising one or more substances for activation of the lectin complement pathway and optionally an inert carrier. The second kit comprises a container comprising a predetermined amount of one or more inhibitors of the classical and the alternative complement pathways and a diluent, wherein the container is adapted for receiving a predetermined amount of sample, so that when the predetermined amount of sample is added, the concentration of the one or more inhibitors is an inhibitory effective concentration of the classical and alternative pathways, but not the lectin pathway. | 08-05-2010 |
Jorn Erland Koch, Ry DK
Patent application number | Description | Published |
---|---|---|
20100028953 | Methods for production of oligonucleotides - The present invention relates to production of oligonucleotides using rolling circle replication, wherein synthesised multimeric oligonucleotides are reduced to mononucleotides using a nicking cassette. Thus, the invention provides a method for the production of oligonucleotides, enabling efficient amplification of oligonucleotides at lengths up to at least 1000 nucleotides and in high amounts contained within a nicking cassette. | 02-04-2010 |
20100047773 | Novel circle probes and their use in the identification of biomolecules - The present invention provides oligonucleotides and methods for efficient detection of target nucleic acids using rolling circle replication. In one aspect, the oligonucleotides of the invention are characteristic in that they can be circularised without an external ligation template. In another aspect, the oligonucleotides of the invention are characteristic in that they can generate a free 3′end of the target nucleic acid necessary for rolling circle replication. The oligonucleotides and detection methods of the invention are useful e.g. as research tool and for diagnosis. | 02-25-2010 |
Jørn Erland Koch, Ry DK
Patent application number | Description | Published |
---|---|---|
20100286290 | ENZYME ACTIVITY ASSAY USING ROLLING CIRCLE AMPLIFICATION - The present invention relates to an enzyme activity assay using rolling circle amplification for verifying that a sample contains the enzyme activity in question. Thus, the present invention pertains to a method for determining the presence or absence of one or more enzyme activities involved in circularising a non-circular oligonucleotide probe in a biological sample. Furthermore, the present invention concerns liquid compositions comprising one or more oligonucleotide probes. Within the scope of the present invention is also a composition comprising a liquid composition and a tissue sample, and solid support of one or more oligonucleotides of the present invention. Disclosed is also a microfluidic device with one or more compartments for performing rolling circle amplification events, and a method for correlating one or more rolling circle amplification events. Methods for testing the efficacy of a drug, for diagnosing or prognosing a disease, for treating a disease, or for treating prophylactically a disease is furthermore disclosed. | 11-11-2010 |
20110027253 | PADLOCK PROBE AMPLIFICATION METHODS - The present invention relates to an enzyme activity assay using rolling circle 5 amplification for verifying that a sample contains enzyme activity. The enzyme activity assayed is typically involved in processing of mismatched nucleotides and/or damaged nucleotides in a double stranded nucleic acid. The present invention relates to methods for determining the presence of enzyme activities involved in processing double stranded oligonucleotide. Methods are also directed against determining the presence | 02-03-2011 |
20140155284 | SYSTEM FOR IDENTIFICATION OF MICROORGANISM AND DETECTION OF INFECTIOUS DISEASE - Methods for the identification of microorganisms or infectious disorders are disclosed, comprising obtaining a suitable sample from sources such as persons, animals, plants, food, water or soil. The methods also comprise providing tailored nucleic acid substrate(s) designed to react with a type 1 topoisomerase from one or more microorganism(s) or infectious agent(s), and incubating said substrate with said sample, or extracts or preparations from the sample, so that the substrate is processed by said topoisomerase if said microorganism(s) or infectious agent(s) is present in the sample. Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are also provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme. | 06-05-2014 |
20150018228 | ENZYME DETECTION BY MICROFLUIDICS - Microfluidic-implemented methods of detecting an enzyme, in particular a DNA-modifying enzyme, are provided, as well as methods for detecting a cell, or a microorganism expressing said enzyme. The enzyme is detected by providing a nucleic acid substrate, which is specifically targeted by that enzyme. | 01-15-2015 |
Kristian Norup Koch, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090239903 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS - The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds. | 09-24-2009 |
20100216840 | BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS - Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M | 08-26-2010 |
20140221364 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS - The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds. | 08-07-2014 |
Mikael Koch, Virum DK
Patent application number | Description | Published |
---|---|---|
20110155753 | CONTAINER - The container ( | 06-30-2011 |
Povi Koch, Kobenhavn DK
Patent application number | Description | Published |
---|---|---|
20090098906 | Electronic Device Having a Cellular Communication Mode and a Radio Communication Mode - An electronic device having a cellular communication mode and a radio communication mode, the electronic device including first transceiver means, operable in the cellular communication mode, for transmitting a message via a cellular network, the message including information for enabling a radio communication mode of a further electronic device; and second transceiver means, operable in the radio communication mode, for communicating with the further electronic device when in the radio communication mode. | 04-16-2009 |
Povl Koch, Smørum DK
Patent application number | Description | Published |
---|---|---|
20140369537 | HEARING ASSISTANCE DEVICE WITH BRAIN COMPUTER INTERFACE - The present disclosure relates to communication devices. Such devices may comprise input for receiving sound signal to be processed and presented to a user, and output for outputting the processed signal to a user perceivable as sound. Such processing may be performed by use of a processor for processing the sound signal in dependence of a setting or a set of setting to compensate a hearing loss profile. Further, the communication device may comprise a bio-signal acquisition and amplifier component in communication with a user interface for providing the bio-signals as input to the user interface, the user interface controlling the setting or set of setting for operation of the communication device. | 12-18-2014 |
Povl Koch, Smorum DK
Patent application number | Description | Published |
---|---|---|
20150289061 | HEARING AID COMPRISING A FLEXIBLE CONNECTION MEMBER - A hearing aid device configured to be inserted into the ear canal of a hearing aid user. The hearing aid includes a receiver, a hearing instrument body, and a connection member extending between the hearing instrument body and the receiver. The connection member is a permanent part of the hearing aid device and the connection member has a stiffness that allows the receiver to be inserted into the ear canal by moving the hearing instrument body towards the eardrum. The connection member comprises means for achieving a first stiffness sufficient large to insert the hearing aid device into the ear canal the connection member comprises means for achieving a second significantly reduced stiffness which makes the hearing aid device comfortable to wear for the user. | 10-08-2015 |
Torben Koch, Copenhagen Nv DK
Patent application number | Description | Published |
---|---|---|
20160002296 | POLYMYXINS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE - Disclosed herein is a composition comprising at least one polymyxin or a salt thereof represented by formula (I) wherein R | 01-07-2016 |
Torben Koch, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20120208981 | Method for purification of colistin and purified colistin components - The present invention concerns a method of purifying colistin using reverse phase chromatography, wherein loading a column with colistin base in acetic acid and high ethanol concentration and eluting with low ethanol concentration is performed. | 08-16-2012 |
Troels Koch, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20090176977 | LNA MODIFIED PHOSPHOROTHIOLATED OLIGONUCLEOTIDES - The current invention provides oligonucleotides which comprise a dinucleotide consisting of a 5′ locked nucleic acid (LNA), a phosphorothioate internucleoside linkage bond to a 3′ RNA or RNA analogue. The dinucleotide reduces the strength of hybridization of the oligonucleotide to a complementary nucleic acid target. The modification can be used to modulate hybridisation properties in both single stranded oligonucleotides and in double stranded siRNA complexes, particularly in oligonucleotides where the use of LNA results in excessively strong hybridisation properties. | 07-09-2009 |
Troels Koch, Copenhagen S DK
Patent application number | Description | Published |
---|---|---|
20080249039 | Modified Short Interfering Rna (Modified Sirna) - The present invention is directed to modified siRNA which are significantly impaired in their ability to support cleavage of mRNA when incorporated into a RISC complex. Such modified siRNA may be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the modified siRNA comprises a sense strand and an antisense strand, wherein the sense strand contains a modified RNA nucleotide in at least one of positions 8-14, calculated from the 5′-end. | 10-09-2008 |
20090209748 | OLIGONUCLEOTIDES WITH ALTERNATING SEGMENTS OF LOCKED AND NON-LOCKED NUCLEOTIDES - The present invention is directed to novel oligonucleotides with improved antisense properties. The novel oligonucleotides comprise at least one Locked Nucleic Acid (LNA) selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. The present invention also provides a new class of pharmaceuticals which comprise antisense oligonucleotides and are useful in antisense therapy. | 08-20-2009 |
20100062994 | Adenosine Receptor Antagonists - The present application discloses locked nucleoside compounds of the Formula I which act as antagonists of adenosine receptors, in particular the adenosine A3 receptor, and the use of such adenosine A3 receptor compounds in medicine, e.g. for the treatment or alleviation or prophylaxis of selected from the group consisting of pain; inflammatory diseases, arthritis, multiple sclerosis, inflammation, asthma and psoriasis; gastro-intestinal disorders; allergy; disorders associated with mast cell or eosinophil activation and degranulation; cardio-vascular disorders; cutaneous diseases; wound healing; opthalmological disorders; respiratory disorders; kidney diseases; central nervous system disorders; Alzheimer's disease, Creutzfeldt-Jacob disease, Huntington's disease and Parkinson's disease; trauma and seizure; diabetes; osteoporosis; diseases of the immune system; cancers, infections; high blood pressure, locomotor hyperactivity, hypertension and depression; acute hypoxia; neonatal hypoxia, hypoxia and chronic hypoxia; and infertility. | 03-11-2010 |
20140128586 | AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN - A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. | 05-08-2014 |
20140128591 | ANTISENSE DESIGN - A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. | 05-08-2014 |
20140194614 | AMINO-LNA, THIO-LNA AND ALPHA-L-OXY-LN - A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. | 07-10-2014 |
20140235844 | Short Interfering RNA (siRNA) Analogues - The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer. | 08-21-2014 |
20140288290 | ANTISENSE DESIGN - A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. | 09-25-2014 |
20140296502 | ANTISENSE DESIGN - A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides. | 10-02-2014 |
Troels Koch, Kobenhavn S DK
Patent application number | Description | Published |
---|---|---|
20100216983 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES - The invention relates to a novel strategy for the synthesis of Locked Nucleic Acid derivatives, such as α- | 08-26-2010 |
20120165514 | SYNTHESIS OF LOCKED NUCLEIC ACID DERIVATIVES - The invention relates to a novel strategy for the synthesis of Locked Nucleic Acid derivatives, such as α- | 06-28-2012 |